EUVIMEDEUVIMED entdecken
Crossref

Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits

Abdulkadir Abdu, Hossamaldeen Bakrey, Israa Abdelrahim, Zeinab Awad, Yassir Abubakar Fikak, Tambe Daniel Atem, Angima Kibari Justine, Mazin Aboobaida Abdalla Abdelaziz, Lina Eltaib

International Journal of Applied Biology and Pharmaceutical Technology · 2026 · 17 (1)

DOI: 10.26502/ijabpt.202144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Applied Biology and Pharmaceutical Technology, 2026. Verfasst von Abdulkadir Abdu und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Abdu, A., Bakrey, H., Abdelrahim, I., Awad, Z., Fikak, Y. A., Atem, T. D., Justine, A. K., Abdelaziz, M. A. A., & Eltaib, L. (2026). Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits. International Journal of Applied Biology and Pharmaceutical Technology, 17(1). https://doi.org/10.26502/ijabpt.202144

Vancouver

Abdu A, Bakrey H, Abdelrahim I, Awad Z, Fikak YA, Atem TD, et al. Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits. International Journal of Applied Biology and Pharmaceutical Technology. 2026;17(1). doi:10.26502/ijabpt.202144

BibTeX
@article{Abdu2026,
  author = {Abdu, Abdulkadir and Bakrey, Hossamaldeen and Abdelrahim, Israa and Awad, Zeinab and Fikak, Yassir Abubakar and Atem, Tambe Daniel and Justine, Angima Kibari and Abdelaziz, Mazin Aboobaida Abdalla and Eltaib, Lina},
  title = {Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits},
  journal = {International Journal of Applied Biology and Pharmaceutical Technology},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.26502/ijabpt.202144}
}
Kostenlos starten →